A Phase 1, Double-Blind, Placebo-Controlled, Sponsor Open, Randomized, Multiple Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04447943 In Healthy Volunteers When Combined With Donepezil.

Trial Profile

A Phase 1, Double-Blind, Placebo-Controlled, Sponsor Open, Randomized, Multiple Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04447943 In Healthy Volunteers When Combined With Donepezil.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs PF 4447943 (Primary) ; Donepezil
  • Indications Alzheimer's disease; Attention deficit and disruptive behaviour disorders; Dementia; Migraine; Vascular dementia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Dec 2017 Results assessing safety and tolerability of PF-04447943 across a clinical trial program in 277 patients (Eight phase 1 studies, One phase II and One phase Ib study) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 20 Jul 2011 Results presented at the 2011 International Conference on Alzheimer's Disease.
    • 03 Aug 2010 Last checked against ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top